{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T14:34:07Z","timestamp":1793457247643,"version":"4.5.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"JSPS KAKENHI","award":["17K09720"],"award-info":[{"award-number":["17K09720"]}]},{"DOI":"10.13039\/501100013489","name":"Yakult Bio-Science Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013489","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.jdiacomp.2018.04.011","type":"journal-article","created":{"date-parts":[[2018,5,4]],"date-time":"2018-05-04T21:36:22Z","timestamp":1525469782000},"page":"720-725","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"title":["Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease"],"prefix":"10.1016","volume":"32","author":[{"given":"Akira","family":"Mima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0005","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Diabetes C, Complications Trial Research G","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0010","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0015","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.2337\/db12-0052","article-title":"Why do SGLT2 inhibitors inhibit only 30\u201350% of renal glucose reabsorption in humans?","volume":"61","author":"Liu","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0020","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","article-title":"Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes","volume":"54","author":"Rahmoune","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0025","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.2337\/db13-0604","article-title":"Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30\u201350% of filtered glucose load in humans","volume":"62","author":"Abdul-Ghani","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0030","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc17-0518","article-title":"Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial","volume":"40","author":"Ito","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0035","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2337\/dc08-1863","article-title":"Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes","volume":"32","author":"List","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0040","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/dom.12189","article-title":"Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2\u202fyears in patients with type 2 diabetes mellitus inadequately controlled on metformin","volume":"16","author":"Bolinder","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0045","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0050","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0055","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2213-8587(13)70084-6","article-title":"Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"1","author":"Roden","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0060","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","article-title":"Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52\u202fweek results from a randomised, double-blind, phase 3 non-inferiority trial","volume":"382","author":"Cefalu","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0065","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1056\/NEJM199807093390202","article-title":"Reversal of lesions of diabetic nephropathy after pancreas transplantation","volume":"339","author":"Fioretto","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0070","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/archinternmed.2011.2230","article-title":"Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes","volume":"172","author":"Coca","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0075","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/ki.1983.72","article-title":"Hemodynamically mediated glomerular injury and the progressive nature of kidney disease","volume":"23","author":"Brenner","year":"1983","journal-title":"Kidney Int"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0080","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1681\/ASN.V2111578","article-title":"Impaired myogenic responsiveness of the afferent arteriole in streptozotocin-induced diabetic rats: role of eicosanoid derangements","volume":"2","author":"Hayashi","year":"1992","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0085","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0090","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0095","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0100","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.2337\/db11-1824","article-title":"Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCbeta activation in diabetes","volume":"61","author":"Mima","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0105","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/archinte.160.5.685","article-title":"Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?","volume":"160","author":"Bakris","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0110","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/ki.2011.79","article-title":"An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function","volume":"80","author":"Holtkamp","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0115","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0120","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1681\/ASN.V10122569","article-title":"Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption","volume":"10","author":"Vallon","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0125","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/07853890.2011.560181","article-title":"A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials","volume":"44","author":"Musso","year":"2012","journal-title":"Ann Med"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0130","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1161\/CIRCULATIONAHA.113.007071","article-title":"Sodium glucose transport 2 (SGLT2) inhibition decreases glomerular hyperfiltration: is there a role for SGLT2 inhibitors in diabetic kidney disease?","volume":"129","author":"Stanton","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0135","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1475-2840-13-28","article-title":"The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus","volume":"13","author":"Cherney","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0140","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.2337\/dc13-2338","article-title":"Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial","volume":"37","author":"Perkins","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0145","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1007\/s00125-014-3396-4","article-title":"Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration","volume":"57","author":"Skrtic","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0150","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jash.2016.01.009","article-title":"Importance of inhibiting sodium-glucose cotransporter and its compelling indication in type 2 diabetes: pathophysiological hypothesis","volume":"10","author":"Kimura","year":"2016","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0155","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12933-014-0148-1","article-title":"Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice","volume":"13","author":"Lin","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0160","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1253\/circj.CJ-16-0780","article-title":"Diuretic action of sodium-glucose cotransporter 2 inhibitors and its importance in the management of heart failure","volume":"80","author":"Kimura","year":"2016","journal-title":"Circ J"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0165","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/ki.1987.39","article-title":"The cortical thick ascending limb and early distal convoluted tubule in the urinary concentrating mechanism","volume":"31","author":"Greger","year":"1987","journal-title":"Kidney Int"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0170","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1681\/ASN.2013060588","article-title":"Functional role of glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on Na+\/H+ exchanger isoform 3 activity in the renal proximal tubule","volume":"25","author":"Pessoa","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0175","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jdiacomp.2013.03.003","article-title":"Diabetic nephropathy: protective factors and a new therapeutic paradigm","volume":"27","author":"Mima","year":"2013","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0180","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/248563","article-title":"Inflammation and oxidative stress in diabetic nephropathy: new insights on its inhibition as new therapeutic targets","volume":"2013","author":"Mima","year":"2013","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0185","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.2337\/db06-0895","article-title":"Reduction of diabetes-induced oxidative stress, fibrotic cytokine expression, and renal dysfunction in protein kinase Cbeta-null mice","volume":"55","author":"Ohshiro","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0190","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.bbrc.2007.06.148","article-title":"Inhibition of MCP-1\/CCR2 pathway ameliorates the development of diabetic nephropathy","volume":"360","author":"Kanamori","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0195","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1161\/CIRCRESAHA.113.301074","article-title":"Induction of vascular insulin resistance and endothelin-1 expression and acceleration of atherosclerosis by the overexpression of protein kinase C-beta isoform in the endothelium","volume":"113","author":"Li","year":"2013","journal-title":"Circ Res"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0200","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2337\/diabetes.52.3.829","article-title":"Characterization of retinal leukostasis and hemodynamics in insulin resistance and diabetes: role of oxidants and protein kinase-C activation","volume":"52","author":"Abiko","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0205","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/cvr\/cvv107","article-title":"PKC-beta activation inhibits IL-18-binding protein causing endothelial dysfunction and diabetic atherosclerosis","volume":"106","author":"Durpes","year":"2015","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0210","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/nm.2052","article-title":"Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy","volume":"15","author":"Geraldes","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0215","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1096\/fj.11-202994","article-title":"Glomerular VEGF resistance induced by PKCdelta\/SHP-1 activation and contribution to diabetic nephropathy","volume":"26","author":"Mima","year":"2012","journal-title":"FASEB J"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0220","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1681\/ASN.2011060628","article-title":"Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes","volume":"23","author":"Gohda","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0225","doi-asserted-by":"crossref","DOI":"10.1038\/srep43520","article-title":"Circulating TNF receptors 1 and 2 predict mortality in patients with end-stage renal disease undergoing Dialysis","volume":"7","author":"Gohda","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0230","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/2211-5463.12400","article-title":"Obesity-associated glomerular inflammation increases albuminuria without renal histological changes","volume":"8","author":"Mima","year":"2018","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0235","article-title":"Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db\/db mice","volume":"6","author":"Gallo","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0240","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1096\/fj.01-0006com","article-title":"Accelerated diabetic glomerulopathy in galectin-3\/AGE receptor 3 knockout mice","volume":"15","author":"Pugliese","year":"2001","journal-title":"FASEB J"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0245","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1096\/fj.02-1102fje","article-title":"The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes","volume":"17","author":"Forbes","year":"2003","journal-title":"FASEB J"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0250","doi-asserted-by":"crossref","first-page":"31S","DOI":"10.1016\/j.amjhyper.2004.08.021","article-title":"Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease","volume":"17","author":"Cooper","year":"2004","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0255","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112394","article-title":"The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity","volume":"9","author":"Oelze","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0260","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1055\/s-0034-1395609","article-title":"Empagliflozin, an inhibitor of sodium-glucose cotransporter 2 exerts anti-inflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-receptor axis","volume":"47","author":"Ojima","year":"2015","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0265","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/ki.2010.526","article-title":"Glomerular-specific protein kinase C-beta-induced insulin receptor substrate-1 dysfunction and insulin resistance in rat models of diabetes and obesity","volume":"79","author":"Mima","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0270","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.86574","article-title":"Insulin decreases atherosclerosis by inducing endothelin receptor B expression","volume":"1","author":"Park","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0275","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3389\/fcvm.2016.00043","article-title":"Glycemic control with Ipragliflozin, a novel selective SGLT2 inhibitor, ameliorated endothelial dysfunction in Streptozotocin-induced diabetic mouse","volume":"3","author":"Salim","year":"2016","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0280","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/00004872-199405000-00001","article-title":"Sympathetics, insulin resistance and coronary risk in hypertension: the \u2018chicken-and-egg\u2019 question","volume":"12","author":"Julius","year":"1994","journal-title":"J Hypertens"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0285","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1681\/ASN.2009111112","article-title":"Heart rate variability predicts ESRD and CKD-related hospitalization","volume":"21","author":"Brotman","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0290","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2337\/diab.40.7.867","article-title":"Validation and evaluation of test for sympathetic cholinergic function in diabetes mellitus","volume":"40","author":"Pestell","year":"1991","journal-title":"Diabetes"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0295","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1161\/01.HYP.25.4.834","article-title":"Renal sympathetic nerve activity is increased in obese Zucker rats","volume":"25","author":"Morgan","year":"1995","journal-title":"Hypertension"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0300","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1053\/j.ajkd.2004.03.026","article-title":"Asymptomatic cerebral lacunae in patients with chronic kidney disease","volume":"44","author":"Kobayashi","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0305","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1038\/ki.1994.211","article-title":"Coexisting NPY and NE synergistically regulate renal tubular Na+, K(+)-ATPase activity","volume":"45","author":"Ohtomo","year":"1994","journal-title":"Kidney Int"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0310","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2174\/157339910790909396","article-title":"Cardiovascular and renal complications of type 2 diabetes in obesity: role of sympathetic nerve activity and insulin resistance","volume":"6","author":"Masuo","year":"2010","journal-title":"Curr Diabetes Rev"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0315","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.jchf.2017.08.018","article-title":"Prognostic importance of temporal changes in resting heart rate in heart failure and preserved ejection fraction: from the TOPCAT study. JACC","volume":"5","author":"Vazir","year":"2017","journal-title":"Heart Fail"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0320","first-page":"184","article-title":"Renal denervation for resistant hypertension","volume":"371","author":"Bhatt","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0325","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/hr.2016.193","article-title":"Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure","volume":"40","author":"Rahman","year":"2017","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0330","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1097\/HJH.0000000000001434","article-title":"Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2","volume":"35","author":"Matthews","year":"2017","journal-title":"J Hypertens"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0335","doi-asserted-by":"crossref","first-page":"457","DOI":"10.14740\/jocmr3011w","article-title":"Hemodynamic effects of sodium-glucose cotransporter 2 inhibitors","volume":"9","author":"Sano","year":"2017","journal-title":"J Clin Med Res"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0340","doi-asserted-by":"crossref","first-page":"51","DOI":"10.5582\/ddt.2017.01069","article-title":"Long-term use of ipragliflozin improved cardiac sympathetic nerve activity in a patient with heart failure: a case report","volume":"12","author":"Kiuchi","year":"2018","journal-title":"Drug Discov Ther"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0345","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1007\/s00125-015-3771-9","article-title":"Role of the renal sympathetic nerve in renal glucose metabolism during the development of type 2 diabetes in rats","volume":"58","author":"Rafiq","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0350","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0355","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.2337\/db13-1029","article-title":"Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen","volume":"63","author":"Kanasaki","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0360","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/ki.2015.103","article-title":"Interactions of DPP-4 and integrin beta1 influences endothelial-to-mesenchymal transition","volume":"88","author":"Shi","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0365","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.clinthera.2013.01.010","article-title":"Effects of LX4211, a dual SGLT1\/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes","volume":"35","author":"Zambrowicz","year":"2013","journal-title":"Clin Ther"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0370","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1124\/jpet.115.225508","article-title":"Intestinal sodium glucose cotransporter 1 inhibition enhances glucagon-like Peptide-1 secretion in normal and diabetic rodents","volume":"354","author":"Oguma","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0375","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jphs.2015.03.006","article-title":"The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats","volume":"127","author":"Oguma","year":"2015","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0380","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1517\/14656566.2015.1088830","article-title":"Combination therapy with saxagliptin and dapagliflozin for the treatment of type 2 diabetes","volume":"16","author":"Williams","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0385","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/dom.12578","article-title":"Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition","volume":"18","author":"Rajeev","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0390","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"CV protection in the EMPA-REG OUTCOME trial: A \u201cthrifty substrate\u201d hypothesis","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0395","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0400","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2337\/dc16-0542","article-title":"Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis","volume":"39","author":"Mudaliar","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0405","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1167\/iovs.11-8447","article-title":"GPR109A as an anti-inflammatory receptor in retinal pigment epithelial cells and its relevance to diabetic retinopathy","volume":"53","author":"Gambhir","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0410","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1126\/science.1227166","article-title":"Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous histone deacetylase inhibitor","volume":"339","author":"Shimazu","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0415","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0420","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/1440-1681.12031","article-title":"Haemodynamic influences on kidney oxygenation: clinical implications of integrative physiology","volume":"40","author":"Evans","year":"2013","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0425","doi-asserted-by":"crossref","first-page":"F227","DOI":"10.1152\/ajprenal.00689.2014","article-title":"Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats","volume":"309","author":"O'Neill","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0430","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.2215\/CJN.00640114","article-title":"Physiology of the renal interstitium","volume":"10","author":"Zeisberg","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0435","doi-asserted-by":"crossref","first-page":"F495","DOI":"10.1152\/ajprenal.00642.2012","article-title":"Sestrin-2 and BNIP3 regulate autophagy and mitophagy in renal tubular cells in acute kidney injury","volume":"305","author":"Ishihara","year":"2013","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0440","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/jbmr.3293","article-title":"Bicarbonate recycling by HIF-1-dependent carbonic anhydrase isoforms 9 and 12 is critical in maintaining intracellular pH and viability of nucleus pulposus cells","volume":"33","author":"Silagi","year":"2018","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0445","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/ki.2013.74","article-title":"Diabetic nephropathy: are there new and potentially promising therapies targeting oxygen biology?","volume":"84","author":"Miyata","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0450","doi-asserted-by":"crossref","first-page":"32162","DOI":"10.1074\/jbc.M111.244541","article-title":"SOX9 protein induces a chondrogenic phenotype of mesangial cells and contributes to advanced diabetic nephropathy","volume":"286","author":"Kishi","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0455","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1172\/JCI57301","article-title":"Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice","volume":"121","author":"Asada","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jdiacomp.2018.04.011_bb0460","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jjcc.2017.12.004","article-title":"A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity","volume":"71","author":"Sano","year":"2018","journal-title":"J Cardiol"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872718302964?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872718302964?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,21]],"date-time":"2022-08-21T22:05:02Z","timestamp":1661119502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872718302964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":92,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S1056872718302964"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2018.04.011","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2018.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}